

## Special Issue

# Mesenchymal Stem Cells in Regenerative Medicine and Immunomodulation

### Message from the Guest Editors

Mesenchymal stem cells (MSCs) represent a heterogeneous population of adult, fibroblast-like, multipotent cells. MSCs have drawn much attention in the field of regenerative medicine over the last decade. Due to their immunomodulatory properties, they are now considered an extraordinary opportunity for multifunctional therapeutic approaches. Since these cells are "immunoprivileged," they may be the first cell type able to be used as an "off-the-shelf" therapeutic product. It has been demonstrated that cultured MSCs have the ability, upon migration, to engraft into healthy as well as injured tissue and can differentiate into several cell types *in vivo*, which makes MSCs an ideal tool for regenerative therapy in different disease types. New observations and reviews of MSCs' immunomodulatory properties and potential mechanisms, as well as their effects on immunomodulation-mediated disease therapies and tissue regeneration, will be of invaluable interest to readers for the future development of MSC-based clinical applications.

---

### Guest Editors

Dr. Biancamaria Longoni  
Dr. Serena Barachini  
Dr. Hiroshi Wakao

---

### Deadline for manuscript submissions

closed (31 August 2023)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/167588](https://mdpi.com/si/167588)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).